Quantum Genomics Announces Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will host a conference call on Thursday, September 29, 2016 at 12:00 p.m. Eastern Time (6:00 p.m. Central European Time) to discuss top-line results from the recently completed Phase IIa clinical trial of lead drug candidate QGC001, in hypertension.
Additional details on access to conference call are as follows:
- Date: Thursday, September 29th, 2016
- Time: 12:00 PM ET/ 6:00 PM CET
- Dial-in numbers: 1-888-740-6143 (U.S.) / 1-913-312-1427 (International)
- Passcode: 6527238
- Replay dial-in numbers: 1-844-512-2921 (U.S.) / 1-412-317-6671 (International)
A brief slide presentation will accompany the call. It will be available prior to the call on the "Investor Presentations" page of the "Investor" section on the Company's website.
- Presentation Link: http://www.quantum-genomics.com/www/en/investors/investors presentations/
CONTACTS
Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
[email protected]
ACTUS finance et communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
[email protected]
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592
Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
[email protected]
ACTUS finance et communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
[email protected]
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Regulated information
News releases under ongoing reporting obligations:
- other releases
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-45718-QUANTUM_PR_QGC001-Webcast_2016092_VDEF_EN.pdf
Receive by email the next press releases of the company by registering on
www.actusnews.com, it's free
Source: Actusnews
Quantum Genomics S.A. Stock
€0.080
-1.110%
